From The Alzheimer's Association International Conference 2016: A 6-Year Trial With A Vascular Care Intervention To Prevent Dementia
PRNewswire-USNewswire/ -- Important clinical trial results in Alzheimer's disease and dementia are being reported at the 2016 Alzheimer's Association International Conference (AAIC 2016) in Toronto, Canada.Scientists from the Netherlands found that a six-year, nurse-led vascular care intervention did not lead to a reduction of all-cause dementia in a cognitively healthy population. However, fewer cases of non-Alzheimer's dementia were observed in the intervention group compared to the control group. In addition, they saw fewer cases of incident dementia in a subgroup of people in the study with untreated hypertension who were adherent to the intervention.
Mercator MedSystems Announces First Patients Enrolled In U.S. Below The Knee (BTK) Clinical Trial In North Carolina And Texas
PRNewswire-USNewswire/ -- Mercator MedSystems, Inc., has announced the enrollment of the first critical limb ischemia (CLI) patients in the LIMBO-ATX trial, the design of which was approved by the U.S. Food and Drug Administration (FDA) under an Investigation New Drug (IND) application. The study is designed to measure the benefit of localized drug delivery using the company's proprietary Bullfrog® Micro-Infusion Device in combination with opening obstructed arteries in the lower leg. Patients were enrolled by Dr. George Adams at the University of North Carolina REX Hospital in Raleigh, NC and by Dr. Jason Yoho of the New Braunfels Cardiology Group at Guadalupe Regional Hospital in Seguin, TX, and both enrollments were in conjunction with an atherectomy procedure.
NAMUR, Belgium, July 27, 2016 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing diagnostic tests for cancer and other conditions, today announced that the U.S. Patent and Trademark Office granted the Company U.S. Patent Number 9,400,276 titled "Method For Detecting Nucleosomes Containing Histone Variants."
Option Care Home Infusion Hemophilia Patients Use Less Factor VIII, Study Shows Cost Savings Without Affecting Outcomes
ORLANDO--(BUSINESS WIRE)--Hemophilia patients can be managed with less factor VIII without affecting outcomes and saving significant costs, suggests a study being presented at the World Federation of Hemophilia 2016 World Congress meeting today in Orlando.
LabCorp Announces Agreement to Acquire Sequenom
BURLINGTON, N.C. & SAN DIEGO--(BUSINESS WIRE)--Laboratory Corporation of America® Holdings (LabCorp®) (NYSE:LH), the world’s leading healthcare diagnostics company, and Sequenom, Inc. (NASDAQ:SQNM), a pioneer in non-invasive prenatal testing (NIPT) for reproductive health, today announced that they have entered into a definitive agreement and plan of merger under which LabCorp would acquire all of the outstanding shares of Sequenom in a cash tender offer for .40 per share, or an equity value of 2 million, which represents a total enterprise value of approximately 1 million, including net indebtedness.
Neurovance Announces Positive Centanafadine Phase 2b Results for Adult ADHD, and Plans for Phase 3 Trials
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Neurovance, Inc. today announced that its Phase 2b trial of centanafadine SR (CTN), a non-stimulant for the treatment of adults with ADHD, met both the primary and secondary endpoints. The trial showed that CTN at 400 mg demonstrated an effect size of 0.6, within the range of the pivotal trials of approved stimulants, the most frequently prescribed drugs in the US for ADHD. The 400 mg dose was generally well tolerated with rates of insomnia and loss of appetite less than typically seen with stimulants. This trial lays the groundwork for future phase 3 trials.
EISAI RECEIVES POSITIVE CHMP OPINION ON NEW INDICATION FOR ANTICANCER AGENT LENVATINIB IN COMBINATION WITH EVEROLIMUS FOR TREATMENT OF ADVANCED RENAL CELL CARCINOMA
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito,“Eisai”) announced today that its European regional headquarters Eisai Europe Ltd. (Location: U.K.) has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on anticancer agent lenvatinib mesylate (generic name,“lenvatinib”) in combination with everolimus for the treatment of adult patients with advanced renal cell carcinoma (RCC) following one prior vascular endothelial growth factor (VEGF) targeted therapy. If approved, lenvatinib will be launched under the brand name Kisplyx® for this indication.
Fluoroquinolone Antibacterial Drugs for Systemic Use: Drug Safety Communication - Warnings Updated Due to Disabling Side Effects
FDA approved changes to the labels of fluoroquinolone antibacterial drugs for systemic use (i.e., taken by mouth or by injection). These medicines are associated with disabling and potentially permanent side effects of the tendons, muscles, joints, nerves, and central nervous system that can occur together in the same patient. As a result, FDA revised the Boxed Warning, FDA’s strongest warning, to address these serious safety issues. In addition, FDA updated other parts of the drug label including the Warnings and Precautions and Medication Guide sections. FDA has determined that fluoroquinolones should be reserved for use in patients who have no other treatment options for acute bacterial sinusitis, acute exacerbation of chronic bronchitis, and uncomplicated urinary tract infections because the risk of these serious side effects generally outweighs the benefits in these patients. For some serious bacterial infections the benefits of fluoroquinolones outweigh the risks, and it is appropriate for them to remain available as a therapeutic option. FDA is continuing to assess safety issues with fluoroquinolones as part of FDA’s usual ongoing review of drugs and will update the public if additional actions are needed. See the FDA Drug Safety Communication for additional information, including a Data Summary and Additional Information for Health Care Professionals and Patients.
Ricks will assume President and CEO roles on January 1, 2017, and become chairman of Lilly's board on June 1, 2017 - Lechleiter will continue as chairman through May 2017INDIANAPOLIS, July 27, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that John C. Lechleiter, Ph.D., chairman, president and chief executive officer, will retire as president and CEO and from the company effective December 31, 2016. Lechleiter will continue on Lilly's board of directors until May 31, 2017, serving as non-executive chairman, at which time he will leave the board. Lilly's board of directors unanimously elected David A. Ricks, currently senior vice president and president, Lilly Bio-Medicines, to assume the role of president and chief executive officer and to join the board on January 1, 2017, and to become chairman of the board on June 1, 2017.